Clinical Trial Update: De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients [Phase 3]

View source ↗

Summary

Phase 3 trial update describing the initiation of de-novo prophylaxis with Letermovir vs Valganciclovir for cytomegalovirus in adult kidney transplant recipient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• PREVYMIS (letermovir)
• Valcyte (valganciclovir)

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Kidney Transplant; Complications, CMV | Phase 3 | Status: ACTIVE_NOT_RECRUITING